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In both Europe and the USA, guideline bodies have limited their 
indications for endocarditis prophylaxis. The UK has taken the bolder 
step of not recommending it at all, but clinicians are appropriately 
cautious in changing long-established practice. South Africa has a 
high burden of rheumatic heart disease and HIV, and inappropriate 
restrictions could have major consequences. However, in areas of 
high prevalence, it is equally concerning to continue with a practice 
that may have little benefit and some potential harm.
The CRASH trial1 demonstrated that corticosteroid use in head 
injury was associated with increased mortality. It was estimated 
that 10 000 patients might have died over the previous few decades 
because of this intervention.2 Clinicians had reasoned that although 
there was no clear evidence of benefit, short-term use seemed 
unlikely to cause harm. This trial serves as a sobering reminder of 
the fallibility of intuitive assumptions of benefit based on biological 
plausibility and weak evidence.
Recently, many guidelines on infective endocarditis (IE) 
prophylaxis have been revised. The National Institute of Health 
and Clinical Excellence (NICE) guideline from the UK does not 
recommend antibiotic prophylaxis in patients with predisposing 
cardiac conditions undergoing dental and non-dental interventional 
procedures.3 Other guidelines still recommend prophylaxis when 
the consequences of developing IE are expected to be most severe, 
or in patients at highest risk.4 These recommendations are based on 
differing interpretations and weighting of the same limited body of 
evidence.
The evidence
Dental and endoscopic procedures may cause transient bacteraemia.5 
IE is sometimes preceded by an interventional procedure, and 
antibiotics given before such procedures reduce the frequency of 
positive blood cultures.6 Although their validity has been questioned, 
antibiotics reduce the frequency of episodes of IE in some animal 
models.7
Bacteraemia detectable by blood culture may occur after more 
than 20% of toothbrushing episodes,8 with even higher frequencies 
in individuals with suboptimal dental hygiene.9 IE can develop 
despite prophylaxis.10 Extractions are often performed because of 
dental sepsis, and it is conceivable that the underlying condition 
produces more cumulative bacteraemic episodes than the treating 
intervention.11
A 2004 Cochrane review, and a 2008 update,12 failed to identify 
any blinded randomised controlled trials (RCTs) on IE prophylaxis 
but found 4 case control studies. Two studies13,14 were felt to be biased 
as information on antibiotic use was unavailable for more than 20% 
of the case patients. A third study included very low-risk patients.15 
The remaining case control study16 did not support a protective effect 
of antibiotic use, and even pooling this with the two studies excluded 
because of bias did not show benefit.
Agha et al.17 pooled all 4 case control studies, regardless of their 
drawbacks, to derive a non-significant odds ratio (OR) of 0.46 (95% 
confidence interval (CI) 0.2 - 1.1). Although the effect size is large, 
benefit was again unproven.
The NICE economic model
The OR of 0.46 from the Agha model was used in the NICE economic 
model18 to provide an estimated 50% relative risk reduction. Most 
modelling of the cost-effectiveness of new medications would stop 
here. If efficacy – the denominator – is not demonstrated to exclude 
a null effect, then the cost-effectiveness ratio is undefined.
The risk of an individual with a predisposing cardiac condition 
developing IE after a procedure was set at 4.1 per million interventions. 
This rate appears to be derived from a calculation in a previous 
economic model19 that specifically addressed patients with mitral 
valve prolapse, and calculated its estimates based on work from the 
1970s. In natural frequencies, the base case estimate of 4.1 per million 
is the same as 1 in 250 000, increasing to at most 1 in 10 000 for 
patients with prosthetic valves.
The probability of fatal anaphylaxis after oral amoxicillin was set at 
zero (no harm) in the model base case.
A multi-national study20 (Hungary, Spain, India and Sweden) 
reported 6 (95% CI 2.4 - 15) cases of anaphylaxis per 100 000 
individuals treated with oral amoxicillin. Mortality rates for 
amoxicillin-associated anaphylaxis are poorly defined, with concerns 
about under-reporting.21 For anaphylaxis in general, mortality is 
estimated to be less than 1%.22 Assuming amoxicillin-associated 
anaphylaxis is no different to other aetiologies, fatal anaphylaxis 
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after oral amoxicillin might be expected in less than one in a million 
patients. An earlier cost-effectiveness study used a figure of 0.9 per 
million.23
Model results – NICE
In the NICE base case analysis, 21 cases of IE would be prevented 
for every 10 million patients given prophylaxis in the presence of a 
predisposing cardiac condition. To prevent one death from IE, one 
would need to treat 2.5 million people. Using the same model, if 
ongoing prophylaxis of 50% efficacy is continued for a lifetime (mean 
of 1.5 dental procedures per year), the NICE group estimated a mean 
quality adjusted life year (QALY) accrual per person of 50 minutes 
over a 50-year time horizon. The cost per QALY was £204 000, which 
is well above the conventional NICE cut-off of £30 000 per QALY. 
The model was able to demonstrate cost-effectiveness for patients at 
high risk (e.g. those with prosthetic valves) but even then only using 
generous risk assumptions.
In the UK, scripts for prophylactic antibiotics for IE fell sharply 
after release of the NICE recommendations, without a significant 
alteration in IE incidence.24 In the tangled terminology of non-
inferiority studies, this early review excluded a rise in incidence 
of more than 9.3%, which was less than the pre-set value of 
15% (determined by background data fluctuations). An alternative 
explanation for the unchanged rate might be that high-risk patients 
in the UK continue to be prescribed antibiotics despite the new 
recommendations.25
Variations in international guidelines
The French IE prophylaxis guideline of 200226 was followed by a 
British Antimicrobial Society report in 2006,27 and the American 
Heart Association guideline of 2007.4 In 2008, NICE28 suggested the 
practice be suspended completely. In 2009, the European Society of 
Cardiology still recommended prophylaxis for high-risk individuals 
in line with the AHA guidelines.29
A further variation arose in the Australasian guidelines,30 where 
prophylaxis was still recommended in ‘Indigenous Australians’ with 
rheumatic heart disease, based on expert opinion that the condition 
was more severe in this group.
The published debate
There is now almost a decade’s worth of lively commentary following 
common themes that can be grouped according to shortcuts and 
pitfalls in our thinking (the taxonomy of heuristics and biases):31,32
1. Denial of any evidence – statements suggesting that in the absence 
of RCTs, decision making is essentially arbitrary. In one instance, 
there was outright refusal even to read the evidence.33 Evidence-
based medicine (EBM) advocates using the best available evidence, 
but acknowledges that sometimes only observational studies are 
available.
2. Causal schema bias – a tendency to be more comfortable with 
explanations incorporating a causal narrative (bacteraemia causes 
IE; antibiotics reduce bacteraemia; therefore antibiotics reduce 
endocarditis). This ‘coherent’ explanation is appealing to many 
clinicians.34
3. Group think – adopting beliefs shared by a group. A shared and 
strongly endorsed guideline gains credibility.35
4. Fundamental attribution error – ignoring alternative explanations 
for endocarditis after an intervention.36
5. Honouring sunk costs – because we have ‘always’ done this, it may 
be worth continuing to invest in the strategy.37
6. Availability heuristic – vivid cases override balanced recollection 
(we remember the active sportsperson who developed an 
IE-associated stroke after a tooth extraction,38 but fail to recall the 
many other patients who didn’t).
7. Ad hominem arguments – disparaging the individual presenting 
the argument.39
8. Risk aversion and asymmetrical value assignments (valuing 
potential losses higher than gains) – potential gains from limiting 
the overuse of antibiotics and avoiding anaphylaxis are seen to be 
less tangible than the potential occurrence of an avoidable episode 
of IE.40
Practical belief revision
Coherence-correspondence models of thinking may explain some 
of the resistance to paradigm shifts described by Kuhn.41 Coherence 
emphasises the existence of a logical explanatory narrative whereas 
correspondence focuses more on empiric observation, with greater 
tolerance for gaps in understanding. Both models have led to 
important advances in medicine.42 Of 124 articles in one journal 
in 2009, 13% were considered ‘reversals’ – new higher quality trials 
that contradicted current practice.43 Initial adoption on the basis of 
physiological principles (coherence) rather than sound evidence was 
a common theme among the reversals.
One cognitive crutch recognises the limited half-life of medical 
truth.44-47 We might change our learning mindset, which from 
medical school days has always been acquisitive (What new things 
did I learn today?) to include the countervailing question (What 
mistaken belief have I relinquished today?).
Shifting between the coherence and correspondence models 
may also be of value. In the current example, paying attention 
to the cracks in the smooth narrative of biological plausibility 
can be punctuated by a review of the (very limited!) numeric 
information.
Local applicability
When international guidelines looking at the same body of evidence 
make differing recommendations, it becomes particularly important 
to achieve local clarity. It may be reasonable to argue that developing 
countries in Africa lack the resources to re-explore the evidence and 
develop their own guidelines, although adaptation of international 
guidelines may be feasible.48-50 Such adaptations should acknowledge 
local factors, e.g. the high prevalence of rheumatic heart disease and 
HIV, and potentially greater IE severity owing to late presentation 
and differing causes of valvular damage. However, these factors affect 
policy effectiveness rather than efficacy. If IE prophylaxis works, 
then a policy of using it will benefit more individuals in areas of high 
prevalence and severity; if it doesn’t work, and is being given to many 
people, there is potential for more harm.
Future directions
Further debate culminating in a consensus position on IE prophylaxis 
in developing countries would be helpful. Prophylaxis has modest 
– if any – value, but a trial six times the size of CRASH would be 
needed to establish clearly whether it does more good than harm. 
It seems unnecessary to retain the traditional recommendations 
when NICE, AHA and ESC have already revised their stance, but 
changing established belief takes time. A pragmatic approach might 
be to emphasise both good dental hygiene and early recognition and 
treatment of established endocarditis, and to de-emphasise reliance 
on an intervention of uncertain benefit.
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It is time 
to dream 
put away your pad and pen 
listen to the night
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